Log in

Relevant bibliographies by topics / Empiric Chemotherapy Dose Reduction / Journal articles

To see the other types of publications on this topic, follow the link: Empiric Chemotherapy Dose Reduction.

Journal articles on the topic 'Empiric Chemotherapy Dose Reduction'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Empiric Chemotherapy Dose Reduction.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Paba, C., J. Sachdev, L. Kronish, M. Jahanzeb, and S. Waheed. "Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy." Journal of Clinical Oncology 26, no. 15_suppl (2008): 20636. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.20636.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gupta, N. K., S. Thorpe, P. Vanderhoff, et al. "Pegfilgrastim can be effectively administered the same day as chemotherapy to prevent neutropenia-related complications." Journal of Clinical Oncology 25, no. 18_suppl (2007): 19571. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.19571.

Full text

Abstract:

19571 Background: Pegfilgrastim has been proven to reduce neutropenia-related complications of chemotherapy. However, the administration of pegfilgrastim 24 hours after chemotherapy treatment often poses an inconvenience for the patients and care givers. Methods: A retrospective chart review of the patients who received pegfilgrastim the same day as chemotherapy was done at a rural oncology practice, where some patients travel more than 100 miles each way for treatment. Incidence of febrile neutropenia (FN), defined as ANC = 500 and temperature =101° F; hospitalization for FN; dose-delay; dose

APA, Harvard, Vancouver, ISO, and other styles

3

Guenther, Chad Michael, Nizar Bhulani, Adam Korenke, et al. "Prescribing patterns for FOLFIRINOX in the real world." Journal of Clinical Oncology 36, no. 4_suppl (2018): 463. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.463.

Full text

Abstract:

463 Background: FOLFIRINOX therapy is associated with improved outcome in patients with gastrointestinal cancers. The regimen can be associated with significant toxicity and empiric dose modifications are often used. We analyzed 1) real-world prescribing patterns of FOLFIRINOX and 2) toxicity of therapy. Methods: Patients undergoing FOLFIRINOX chemotherapy at an academic, NCI-Designated Comprehensive Cancer Center were identified and electronic medical records reviewed. Patients who received at least one dose of FOLFIRINOX were included. Chemotherapy dose, growth factor use and toxicity data w

APA, Harvard, Vancouver, ISO, and other styles

4

Thwin, Malar, Aye Min Soe, Nay Min Tun, and Gina M. Villani. "Pattern of chemotherapy dosing in obese patients in a community hospital." Journal of Clinical Oncology 30, no. 15_suppl (2012): e13099-e13099. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13099.

Full text

Abstract:

e13099 Background: Obesity has increased to epidemic proportions, with 32.2% of US adults aged 20 years or older classified as obese (body mass index ≥ 30 mg/m2). In view of altered pharmacokinetics and possible excessive toxicity in obese patients, chemotherapy dose reductions are often employed in treating obese cancer patients. To our knowledge, there are no reports in the literature identifying patients who should have empiric dose adjustment because of obesity or the best method of dosing chemotherapy to standardize drug exposure in patients with varying degrees of obesity. As practice va

APA, Harvard, Vancouver, ISO, and other styles

5

Ganti, Arun, Weijian Liu, Kristen M. Sanfilippo, and Kenneth R. Carson. "Impact of BMI On Treatment-Related Toxicity in United States Veterans with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CHOP+/−R." Blood 120, no. 21 (2012): 3172. http://dx.doi.org/10.1182/blood.v120.21.3172.3172.

Full text

Abstract:

Abstract Abstract 3172 Background: Obesity is associated with an increase in all-cause mortality, much of which is due to cancer. Recently, we demonstrated improved survival in overweight and obese Veterans with DLBCL. To better understand this survival disparity, we explored the frequency of dose-reductions and treatment-related mortality (TRM) as they relate to BMI in this population. Methods: We identified a cohort of DLBCL patients diagnosed between 1998 and 2008 in the Veterans Health Administration (VHA) central cancer registry. Additional data on height, weight, treatment drug, dose, da

APA, Harvard, Vancouver, ISO, and other styles

6

Yu, J., N. M. Reddy, A. Rajput, J. Smith, G. Yang, and M. Fakih. "Outcomes and toxicities among octogenarians and nonagenarians with colorectal cancer (crc) treated with chemotherapy or concurrent chemoradiation - a single institution study." Journal of Clinical Oncology 24, no. 18_suppl (2006): 13514. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.13514.

Full text

Abstract:

13514 Background: Chemotherapy is associated with an improved overall survival with acceptable toxicities in patients ≥ 70 years. However, little to no data exists regarding feasibility and tolerability of chemotherapy and/or radiation in CRC patients ≥ 80 years. The purpose of this study was to identify the trends of increased toxicity in this subgroup of patients. Methods: A retrospective study on patients ≥ 80 yrs treated for CRC with either chemotherapy alone or chemoradiation during the period of 1996- 2005 at Roswell Park Cancer Institute was conducted. Survival analysis was performed us

APA, Harvard, Vancouver, ISO, and other styles

7

Hourdequin, Kathryn Cunningham, William Lewis Schpero, Breanne Lee Piazik, Dorothy R. McKenna, and Robin Joyce Larson. "Toxicity of chemotherapy dosing using actual body weight in obese versus normal-weight patients: A systematic review and meta-analysis." Journal of Clinical Oncology 30, no. 15_suppl (2012): 6013. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6013.

Full text

Abstract:

6013 Background: Because weight-based chemotherapy calculations can be very large in obese patients, oncologists often empirically reduce doses due to fear of excess toxicity. The resulting underdosing may negatively impact survival. We performed a systematic review and meta-analysis to determine whether, among adults receiving chemotherapy dosed by actual body weight (ABW), obese patients experience differing toxicity or survival compared to normal-weight patients. Methods: We searched MEDLINE, Cochrane Library, Web of Science, and ClinicalTrials.gov through October 2011 and reviewed referenc

APA, Harvard, Vancouver, ISO, and other styles

8

Rosero, Gustavo, Gisela Pattarone, Ana Peñaherera, et al. "Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1)." PLOS ONE 17, no. 9 (2022): e0274911. http://dx.doi.org/10.1371/journal.pone.0274911.

Full text

Abstract:

Low-dose metronomic (LDM) chemotherapy is an alternative to conventional chemotherapy and is the most frequently used approach in low dose chemotherapy regimens. The selection of patients, drug dosages, and dosing intervals in LDM is empirical. In this study, we systematically examined the schedule-dependent interaction of drugs on a breast cancer cell line (BCC) cultured in chambered coverslips. The LDM studies were combined with cell staining in order to better characterize different cell states and cell death modes, including caspase-dependent apoptosis, caspase-independent cell death and a

APA, Harvard, Vancouver, ISO, and other styles

9

Veatch, Joshua R., Ravinder K. Sandhu, Kathleen Shannon-Dorcy, et al. "NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)." Blood 120, no. 21 (2012): 1479. http://dx.doi.org/10.1182/blood.v120.21.1479.1479.

Full text

Abstract:

Abstract Abstract 1479 Abnormal values for creatinine, bilirubin, AST, and ALT following chemotherapy, in particular in phase 1 trials, are interpreted using NCI common toxicity criteria. By convention, grade 3 or 4 toxicity leads to dose reduction while grade 1 or 2 toxicity does not. However, grade 3 – 4 toxicity is typically asymptomatic, calling into question the relevance of these criteria. In an attempt to provide a more empirical basis for decisions we analyzed the relation between (a) grades of NCI toxicity for bilirubin, creatinine, ALT, and AST following chemotherapy for AML and (b)

APA, Harvard, Vancouver, ISO, and other styles

10

Dower, Joshua, Yana Salei, Benjamin Koethe, et al. "Tolerability, dose intensity, and prescribing patterns of capecitabine by race." Journal of Clinical Oncology 42, no. 16_suppl (2024): e23278-e23278. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e23278.

Full text

Abstract:

e23278 Background: Capecitabine (cap) is approved for the treatment of breast and colorectal cancer and is used off-label to treat other solid malignancies. Approved dosing varies by indication and concurrent therapies, and the initial dose of cap may be modified empirically based on different patient characteristics. Race/ethnicity have been used by some providers as factors in prescribing patterns. However, the tolerability of cap among patients of different racial/ethnic backgrounds is unknown. Here, we present an updated analysis outlining the tolerability of cap among patients of differen

APA, Harvard, Vancouver, ISO, and other styles

11

Kasenda, Benjamin, Marcel Rehberg, Melanie Franzem, et al. "Mathematical Modeling in Optimizing Methotrexate-Based Chemotherapy." Blood 114, no. 22 (2009): 4766. http://dx.doi.org/10.1182/blood.v114.22.4766.4766.

Full text

Abstract:

Abstract Abstract 4766 Introduction Optimization of doses and administration schedules for anticancer drugs is crucial for effective and safe treatment. Since chemotherapy (CT) remains based predominately on empiric data, the creation of a mathematical model describing the complex interplay between dosing, tumor-response, agents' clearance, and toxicity, presents the opportunity to optimize treatment strategies of established but also new drugs. Primary central nervous system lymphoma (PCNSL) is a rare disease whose incidence is rising. Standard treatment of methotrexat (MTX) based CT has been

APA, Harvard, Vancouver, ISO, and other styles

12

Greenberg, Peter L., Sandra J. Lee, Ranjana Advani, et al. "Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)." Journal of Clinical Oncology 22, no. 6 (2004): 1078–86. http://dx.doi.org/10.1200/jco.2004.07.048.

Full text

Abstract:

Purpose To determine whether adding the multidrug resistance gene-1 (MDR-1) modulator valspodar (PSC 833; Novartis Pharmaceuticals, Hanover, NJ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Patients and Methods A phase III randomized study was performed using valspodar plus mitoxantrone, etoposide, and cytarabine (PSC-MEC; n = 66) versus MEC (n = 63) to treat patients with relapsed or refractory AML and high-risk MDS. Results For the PSC-MEC versus MEC arms, complete response (CR) was achieved in

APA, Harvard, Vancouver, ISO, and other styles

13

Haigentz, Missak, Page C. Moore, Lee Ratner, et al. "Tolerability of paclitaxel/carboplatin (PCb) in solid tumor patients (pts) infected with HIV." Journal of Clinical Oncology 35, no. 15_suppl (2017): e14077-e14077. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14077.

Full text

Abstract:

e14077 Background: Although cancer has long been a recognized hallmark of the HIV epidemic, the preservation of immunologic health with modern antiretroviral therapy (ART) and aging has resulted in a population increasingly susceptible to cancers not traditionally associated with advancing immunosuppression. Several of these cancers (including lung, anal and head & neck) are seen in excess compared to the background population. Defining tolerability of standard treatments and analyzing potential interactions between ART and chemotherapy provides evidence necessary to mitigate treatment dis

APA, Harvard, Vancouver, ISO, and other styles

14

Tun, Nay Min, Elizabeth Guevara, and Thein H. Oo. "Benefit and Risk of Primary Thromboprophylaxis in Ambulatory Patients with Advanced Pancreatic Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Blood 124, no. 21 (2014): 4266. http://dx.doi.org/10.1182/blood.v124.21.4266.4266.

Full text

Abstract:

Abstract Background: Vascular thromboembolism (VTE) is the second leading cause of death in patients with cancer. Despite the fact that mortality is increased in cancer patients who developed VTE compared to those without VTE, empirical prophylaxis against VTE in ambulatory patients with cancer remains controversial. The risk of VTE is higher for certain types of cancer such as pancreatic and hematologic malignancies, in patients with advanced cancer, and in those who are undergoing chemotherapy or radiotherapy. We carried out a systematic review and meta-analysis of randomized controlled tria

APA, Harvard, Vancouver, ISO, and other styles

15

Miao, Yimei, Gerald A. Soff, Rekha Parameswaran, Jonathan Wills, and Simon Mantha. "Enoxaparin Dose Reduction for Thrombocytopenia in Patients with Cancer: A Quality Assessment Study." Blood 126, no. 23 (2015): 429. http://dx.doi.org/10.1182/blood.v126.23.429.429.

Full text

Abstract:

Abstract Background: The development of chemotherapy-induced thrombocytopenia (CIT) in the setting of therapeutic anticoagulation for venous thromboembolic (VTE) disease is a common problem in cancer patients. The current approach to low molecular weight heparin (LMWH) dosing in the setting of CIT (Lee, AYY. J. Clin. Onc. 2009) is empirical and based on limited published experience. This approach was never validated prospectively. Since 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented a similar guideline: administer full dose LMWH for a platelet count >50,000/mcL, half dose

APA, Harvard, Vancouver, ISO, and other styles

16

Lai, Catherine, Diane Cole, Nicole Lucas, et al. "Pharmacokinetics and Tolerability of Etoposide in Newly Diagnosed Lymphoma Patients with Hepatic Impairment." Blood 124, no. 21 (2014): 4445. http://dx.doi.org/10.1182/blood.v124.21.4445.4445.

Full text

Abstract:

Abstract Background: The addition of etoposide to chemotherapy regimens (e.g.- CHOEP and EPOCH) may be beneficial for the treatment of aggressive lymphomas. Previous studies have shown decreased clearance of etoposide in hepatic impairment leading to a dose reduction or removal of drug. Total clearance of etoposide does not change significantly in patients with elevated bilirubin. However, free (or unbound) etoposide levels are a more accurate measurement of drug clearance (Stewart el al. Changes in the Clearance of Total and Unbound Etoposide in Patients with Liver Dysfunction. J Clin Oncol.

APA, Harvard, Vancouver, ISO, and other styles

17

Liles, W. Conrad, and David C. Dale. "Current Approach to the Management of Neutropenia." Journal of Intensive Care Medicine 10, no. 6 (1995): 283–93. http://dx.doi.org/10.1177/088506669501000603.

Full text

Abstract:

Neutrophils have a critical role in host defense. Reduction in the absolute neutrophil count to below 1,000/μL is associated with increased susceptibility to infection. The pattern of infections depends on the severity and the duration of neutropenia and other associated defects in host defense mechanisms and exposure to antibiotics and other drugs, particularly corticosteroids and immunosuppressive agents. Breaks in the integrity of the skin or the gastrointestinal mucosal surfaces serve as the portals of entry for the majority of infecting organisms. Empiric antibiotic therapy and hospitaliz

APA, Harvard, Vancouver, ISO, and other styles

18

Lane, Andrew A., Philippe Armand, Yang Feng, et al. "Risk Factors Associated with the Development of Pneumonitis After High-Dose Chemotherapy with Cyclophosphamide, BCNU, and Etoposide (CBV) Followed by Autologous Stem Cell Transplant." Blood 116, no. 21 (2010): 903. http://dx.doi.org/10.1182/blood.v116.21.903.903.

Full text

Abstract:

Abstract Abstract 903 Background: High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) is a standard component of therapy for some patients with hematologic malignancies, particularly those with relapsed or refractory lymphoma. No high-dose chemotherapy regimen has been shown to be superior to another, and thus regimens are chosen based on institutional standards and toxicity profiles. Pneumonitis is a recognized complication of HDC regimens containing BCNU. There has not been a large study of uniformly-treated lymphoma patients to define the incidence and risk factors for

APA, Harvard, Vancouver, ISO, and other styles

19

Kurt, Beth, Patricia Flynn, Jerry Shenep, et al. "Prophylactic Antibiotics Reduce Morbidity from Septicemia during Intensive Treatment for Pediatric Acute Myelogenous Leukemia." Blood 108, no. 11 (2006): 1919. http://dx.doi.org/10.1182/blood.v108.11.1919.1919.

Full text

Abstract:

Abstract Patients with acute myeloid leukemia (AML) who receive intensive chemotherapy regimens containing high-dose cytarabine are at high risk for bacterial sepsis due to prolonged neutropenia and severe mucositis. To determine if the use of prophylactic antibiotics during periods of neutropenia reduced bacterial infections and viridans streptococcal infections (VSI) in particular, we reviewed the charts of 66 AML patients who were treated on our front line protocol (AML02) from October 2002 to June 2006. During this time, several consecutive prophylactic antibiotic strategies were implement

APA, Harvard, Vancouver, ISO, and other styles

20

Karol, James, Lisa Rybicki, John Sweetenham, et al. "Similar Incidence Of Febrile Neutropenia With Same-Day Versus Subsequent Day G-CSF Administration In Non-Hodgkin Lymphoma Patients Receiving R-CHOP Chemotherapy." Blood 122, no. 21 (2013): 4357. http://dx.doi.org/10.1182/blood.v122.21.4357.4357.

Full text

Abstract:

Abstract Background The chemotherapy regimen of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) every 21 days remains a standard first line treatment for many subtypes of B-cell non-Hodgkin lymphoma (NHL). R-CHOP chemotherapy carries a significant risk of febrile neutropenia (FN). FN is a potentially life threatening complication which typically requires hospital admission and empiric administration of broad spectrum antibiotics. FN can also cause delays and dose reductions with treatment, which are associated with poorer outcomes. Granulocyte colony stimulating

APA, Harvard, Vancouver, ISO, and other styles

21

Cubero, Daniel I. G., Felipe Melo Cruz, Patrícia Santi, Ismael Dale C. G. Silva, and Auro del Giglio. "Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle." Therapeutic Advances in Medical Oncology 4, no. 4 (2012): 167–72. http://dx.doi.org/10.1177/1758834012441049.

Full text

Abstract:

Objective: The objective of this study was to evaluate the safety of using tegafur–uracil (UFT) in colorectal cancer patients with partial dihydropyrimidine dehydrogenase (DPD) deficiency. Patients and Methods: The study included five colorectal cancer patients who presented with acute toxicity (grades 3 and 4) after being given the first cycle of chemotherapy using 5-fluorouracil. The DPD deficiency was confirmed by gene sequencing. After a full recovery from all side effects, we changed the regimen to UFT (300 mg/m2/day) associated with leucovorin (90 mg/day) for 21 days, with an empirical d

APA, Harvard, Vancouver, ISO, and other styles

22

Kononenko, I. B., A. V. Snegovoy, O. P. Grebennikova, V. Yu Sel’chuk, and O. V. Palchinskaia. "Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy." Journal of Modern Oncology 22, no. 3 (2020): 133–41. http://dx.doi.org/10.26442/18151434.2020.3.200279.

Full text

Abstract:

Neutropenia is a common hematological complication of chemotherapy (СT). The number of studies showed that the underperformance of the treatment program due to the development of this type of hematological toxicity could lead to the decrease in therapy efficacy and to the increase in cancer mortality. Infections that occur as a result of prolonged neutropenia are extremely dangerous. The most severe manifestation of grade 4 neutropenia is febrile neutropenia (FN), which can lead to death from severe infections. Such patients should be immediately hospitalized and should receive empirical thera

APA, Harvard, Vancouver, ISO, and other styles

23

Cornely, Oliver, Thibaut Leguay, Johan Maertens, et al. "A Double-Blind, Multicentre, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukaemia (AmBiGuard trial)." Blood 124, no. 21 (2014): 3646. http://dx.doi.org/10.1182/blood.v124.21.3646.3646.

Full text

Abstract:

Abstract Background: Adult patients undergoing remission-induction (RI) chemotherapy for newly diagnosed acute lymphoblastic leukaemia (ALL) are at high risk of invasive fungal disease (IFD), particularly invasive aspergillosis. The prevalence of IFD in this population has not been widely studied. There is currently no approved standard for antifungal prophylaxis and it is recommended by the European Working Group for Adult ALL that azole antifungal agents be avoided because of drug interactions with vincristine, a standard component of induction chemotherapy regimens. Methods: This was a doub

APA, Harvard, Vancouver, ISO, and other styles

24

Collins, Jennifer, Katherine Shea, Sandeep Parsad, Kelly Plach, and Pauline Lee. "The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation." Journal of Oncology Pharmacy Practice 26, no. 1 (2019): 5–12. http://dx.doi.org/10.1177/1078155219833440.

Full text

Abstract:

Background Posaconazole reduces the risk of invasive Aspergillus in transplant patients, but significantly inhibits tacrolimus metabolism. One study demonstrated that a three-fold dose reduction of tacrolimus was required to obtain therapeutic concentrations when used with posaconazole. However, with empiric dose reduction, there is a risk of subtherapeutic tacrolimus levels and subsequent graft failure or graft-versus-host disease. Overall, the existing data on the impact of posaconazole on tacrolimus pharmacokinetics is limited. Objective The purpose of this study is to determine whether tac

APA, Harvard, Vancouver, ISO, and other styles

25

Kuwana, Tsukasa, Kosaku Kinoshita, Yurina Yamaya, et al. "The Time Course of Catecholamine Dose Reduction in Septic Shock as a Predictor of Bacterial Susceptibility to Empiric Antimicrobial Therapy: A Retrospective Observational Study." Journal of Clinical Medicine 13, no. 21 (2024): 6618. http://dx.doi.org/10.3390/jcm13216618.

Full text

Abstract:

Background/Objectives: The 28-day mortality rate for septic shock is high, necessitating rapid and effective empiric antimicrobial therapy. In this study, we investigate whether the rate of catecholamine dose reduction in septic shock can indicate bacterial susceptibility to initial antimicrobial therapy or not. Methods: This retrospective observational study involved 108 adult patients with bacteraemia and septic shock admitted to the intensive care unit of Nihon University Itabashi Hospital between January 2017 and December 2023. They were classified into the Susceptible or Resistant groups

APA, Harvard, Vancouver, ISO, and other styles

26

Abramson, Jeremy S., and Margaret A. Shipp. "Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach." Blood 106, no. 4 (2005): 1164–74. http://dx.doi.org/10.1182/blood-2005-02-0687.

Full text

Abstract:

AbstractDiffuse large B-cell lymphoma (DLBCL) displays striking heterogeneity at the clinical, genetic, and molecular levels. Clinical prognostic models can define a population at high risk for relapse following empiric chemotherapy, although such models do not account for underlying biologic differences among tumors. Commonly observed genetic abnormalities that likely contribute to pathogenesis include translocations of BCL6, BCL2, cMYC, and FAS(CD95) mutations, and aberrant somatic hypermutation. Despite recent advances in empiric chemotherapy, including interval reduction of CHOP (cyclophos

APA, Harvard, Vancouver, ISO, and other styles

27

Thompson, Lisa A., Amber P. Lawson, Stephanie D. Sutphin, Douglas Steinke, and Val R. Adams. "Description of Current Practices of Empiric Chemotherapy Dose Adjustment in Obese Adult Patients." Journal of Oncology Practice 6, no. 3 (2010): 141–45. http://dx.doi.org/10.1200/jop.200016.

Full text

Abstract:

Medical literature is not clear on the best method to empirically dose chemotherapy in obese adult patients. This study sought to characterize current practices and identify factors affecting such decisions.

APA, Harvard, Vancouver, ISO, and other styles

28

Sengar, Manju, Mounika Boppana, Hasmukh Jain, et al. "Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis." Blood 134, Supplement_1 (2019): 2600. http://dx.doi.org/10.1182/blood-2019-129948.

Full text

Abstract:

Background: Invasive fungal infections (IFIs) continue to remain a significant cause of morbidity and mortality in AML patients affecting the final outcomes and increasing health care costs. Posaconazole is commonly used as prophylaxis against IFIs due to its broad spectrum of action. The incidence of breakthrough IFIs is particularly high in our setting - one of the several reasons being suboptimal drug levels as we use posaconazole suspension whose absorption is influenced by multiple factors. A breakthrough IFI rate of 51% was seen in a previous study from our centre by Sengar et.al (ASH 20

APA, Harvard, Vancouver, ISO, and other styles

29

Kufel, Wesley D., Paul M. Armistead, Lindsay M. Daniels, Jonathan R. Ptachcinski, Maurice D. Alexander, and J. Ryan Shaw. "Drug–Drug Interaction Between Isavuconazole and Tacrolimus: Is Empiric Dose Adjustment Necessary?" Journal of Pharmacy Practice 33, no. 2 (2018): 226–30. http://dx.doi.org/10.1177/0897190018790688.

Full text

Abstract:

A paucity of data currently exists regarding drug–drug interaction (DDI) with tacrolimus and isavuconazole coadministration. Current literature provides conflicting recommendations on whether an empiric tacrolimus dose reduction is necessary when coadministered with isavuconazole. A 47-year-old African American female with acute lymphoblastic leukemia underwent an allogenic stem cell transplant (alloSCT) and was subsequently placed on routine posttransplant therapy including tacrolimus for immunosuppression and posaconazole for antifungal prophylaxis. Tacrolimus was empirically dose reduced du

APA, Harvard, Vancouver, ISO, and other styles

30

Zhang, Xia, Hongjuan Zheng, Cheng Cai, et al. "Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment." PeerJ 11 (September 12, 2023): e15995. http://dx.doi.org/10.7717/peerj.15995.

Full text

Abstract:

Objectives To determine the relationship between chemotherapy dose delay/reduction with progression-free survival (PFS) and overall survival (OS) in colorectal cancer patients treated with FOLFIRI based first-line chemotherapy in real-world retrospectively study. Methods We identified 144 eligible patients with advanced CRC who received FOLFIRI as first-line based treatment. The study protocol was submitted to the institutional review board and was exempted. Dose delay was defined as an average delay of more than 3 days (>3 days vs. ≤3 days) from the intended date. Dose reduction (actual do

APA, Harvard, Vancouver, ISO, and other styles

31

Kalaycioglu, Matt, Mani Kavuru, Laurie Tuason, and Brian Bolwell. "Empiric Prednisone Therapy for Pulmonary Toxic Reaction After High-Dose Chemotherapy Containing Carmustine (BCNU)." Chest 107, no. 2 (1995): 482–87. http://dx.doi.org/10.1378/chest.107.2.482.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Munker, Stefan, Michael Gerken, Petra Fest, et al. "Chemotherapy for metastatic colon cancer: Effect on survival when the dose is reduced due to side effects." Journal of Clinical Oncology 35, no. 4_suppl (2017): 761. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.761.

Full text

Abstract:

761 Background: 5-Fluorouracil (5FU), Folinic acid (FA), and Oxaliplatin (FOLFOX) or 5FU, FA, and Irinotecan (FOLFIRI) are standard regimens for palliative chemotherapy of metastatic colon cancer. Since data showing the influence of dose reduction in palliative treatment are rare, the objective of this single center, retrospective study was to further characterize the influence of dose reduction on efficacy of these therapeutic regimens. Methods: 109 patients, diagnosed with stage IV colon cancer between 2004 and 2012 and receiving palliative first-line chemotherapy with either FOLFOX or FOLFI

APA, Harvard, Vancouver, ISO, and other styles

33

Koba, Yusuke, Kazuhiro Bandai, Naoko Hiranuma, et al. "Retrospective Analysis of the Impact of Bendamustine Dose Reduction and Chemotherapy on the Outcomes of Follicular Lymphoma." Blood 142, Supplement 1 (2023): 6167. http://dx.doi.org/10.1182/blood-2023-179228.

Full text

Abstract:

Introduction Follicular lymphoma (FL) is the most common indolent non-Hodgkin's lymphoma and primarily affects the elderly population. While bendamustine serves as a pivotal drug in standard therapy, it is often not administered as planned due to side effects, especially among the elderly. Clinical studies have shown that dose reduction and chemotherapy delays in the treatment of diffuse large B-cell lymphoma are associated with lower survival rates. However, few studies have analyzed the impact of bendamustine delays and dose reduction on the outcome of FL. Thus, the aim of our study was to c

APA, Harvard, Vancouver, ISO, and other styles

34

Wildner, Dane, Frank Boxberger, Axel Wein, et al. "Granulomatous Lung Disease Requiring Mechanical Ventilation Induced by a Single Application of Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Case Report." Case Reports in Oncological Medicine 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/683948.

Full text

Abstract:

Combined chemotherapeutic regimens in conjunction with oxaliplatin are considered safe and effective treatment options in the clinical management of metastatic colorectal cancer. A 62-year-old male patient with a metastatic rectal carcinoma developed a pulmonary reaction after the first application of the combined standard chemotherapy regimen (5-fluorouracil and sodium folinic acid as a 24 h infusion and oxaliplatin). Following the first dose of chemotherapy, the patient developed acute dyspnoea and fever. A computerised scan of the chest revealed bilateral pulmonary patchy consolidation. Des

APA, Harvard, Vancouver, ISO, and other styles

35

Crathorne, Louise, Nicola Huxley, Marcela Haasova, et al. "The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model." Health Technology Assessment 20, no. 13 (2016): 1–588. http://dx.doi.org/10.3310/hta20130.

Full text

Abstract:

BackgroundAnaemia is a common side effect of cancer treatments and can lead to a reduction in quality of life. Erythropoiesis-stimulating agents (ESAs) are licensed for use in conjunction with red blood cell transfusions to improve cancer treatment-induced anaemia (CIA).ObjectiveTo investigate the effectiveness and cost-effectiveness of ESAs in anaemia associated with cancer treatment (specifically chemotherapy).Data sourcesThe following databases were searched from 2004 to 2013: The Cochrane Library, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Web of Science, Cumula

APA, Harvard, Vancouver, ISO, and other styles

36

Chang, J. "Chemotherapy dose reduction and delay in clinical practice." European Journal of Cancer 36 (April 2000): 11–14. http://dx.doi.org/10.1016/s0959-8049(99)00259-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Wildiers, Hans. "Mastering chemotherapy dose reduction in elderly cancer patients." European Journal of Cancer 43, no. 15 (2007): 2235–41. http://dx.doi.org/10.1016/j.ejca.2007.06.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Leatheng, Chanbormey, Adam Ephraim, and Gabriel A. Brooks. "Retrospective study of fluoropyrimidine chemotherapy dosing and toxicity in patients with screen-detected deleterious DPYD gene variants." Journal of Clinical Oncology 43, no. 4_suppl (2025): 293. https://doi.org/10.1200/jco.2025.43.4_suppl.293.

Full text

Abstract:

293 Background: Fluoropyrimidine chemotherapy agents are commonly used to treat solid tumors. Fluoropyrimidines are degraded by the enzyme dihydropyridine dehydrogenase (DPD), encoded by the DPYD gene. Deleterious variants in DPYD leads to functional DPD deficiency and increased toxicity risk. Methods: We conducted a retrospective study of patients with screen-detected deleterious DPYD variants who were treated with fluoropyrimidine chemotherapy between 01/01/15-04/15/23. Outcomes of interest were initial fluoropyrimidine dosing, dose adjustments (cycles 2-6), and early toxicities. Results: We

APA, Harvard, Vancouver, ISO, and other styles

39

Turati, Virginia A., Javier Herrero Sanchez, Jeffrey West, et al. "Abstract B023: An integrated approach to understanding the evolutionary dynamics of childhood acute lymphoblastic leukemia from diagnosis to relapse." Cancer Research 82, no. 10_Supplement (2022): B023. http://dx.doi.org/10.1158/1538-7445.evodyn22-b023.

Full text

Abstract:

Abstract Up to 20% of children with acute lymphoblastic leukemia (cALL) will relapse after initially responding to treatment. Dissecting the evolutionary population dynamics leading to relapse would help explain treatment failure from a mechanistic standpoint, aiding the design of more effective therapies. Comparisons of genetic heterogeneity at diagnosis and relapse have shown that relapse is often dominated by either a specific diagnostic subclone or its evolutionary progeny, leading to the idea that selection during treatment of cALL primarily operates at the genotype level. However, due to

APA, Harvard, Vancouver, ISO, and other styles

40

Kantor, Elizabeth D., Kelli O’Connell, Isaac J. Ergas, et al. "Abstract P3-03-09: Assessment of Breast Cancer Chemotherapy Dose Reduction in an Integrated Healthcare Delivery System." Cancer Research 83, no. 5_Supplement (2023): P3–03–09—P3–03–09. http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-03-09.

Full text

Abstract:

Abstract Background: Most cytotoxic drugs are dosed according to body surface area (BSA), yet not all patients receive the full BSA-determined dose. Prior work suggests that dose reduction may occur more frequently in obese patients, likely due to concern about inducing toxicity at high doses. Other factors, such as race/ethnicity, have been suggested to be associated with dosing, yet the factors associated with dose reduction remain poorly understood, with little known about dosing patterns in integrated healthcare delivery systems and how such patterns have changed over time. Methods: We exa

APA, Harvard, Vancouver, ISO, and other styles

41

Raissouni, Soundouss, Dawn Elizabeth Armstrong, Julie A. Price Hiller, et al. "Predictors of treatment interruption/dose reduction of neoadjuvant chemotherapy for rectal cancer: A multicenter study." Journal of Clinical Oncology 32, no. 3_suppl (2014): 580. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.580.

Full text

Abstract:

580 Background: Neoadjuvant chemoradiation (CRT) is the standard of care for patients with locally advanced rectal cancer. Many patients require dose reduction or chemotherapy interruption due to significant toxicities. To assess the predictors of neoadjuvant chemotherapy treatment (tx) adjustments, we performed a retrospective study in four Canadian provinces. Methods: Cancer Registries identified consecutive patients with clinical stage I-III rectal cancer from the Tom Baker Cancer Center, Cross Cancer Institute, BC Cancer Agency, Ottawa Hospital Cancer Centre and the Dr. H. Bliss Murphy Can

APA, Harvard, Vancouver, ISO, and other styles

42

Family, Leila, Lanfang Xu, Hairong Xu, et al. "The effect of chemotherapy-induced anemia on dose reduction and dose delay." Supportive Care in Cancer 24, no. 10 (2016): 4263–71. http://dx.doi.org/10.1007/s00520-016-3258-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Adams, Anita, Tamana Hafid, Kari Kolm, et al. "Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy." Blood 114, no. 22 (2009): 1390. http://dx.doi.org/10.1182/blood.v114.22.1390.1390.

Full text

Abstract:

Abstract Abstract 1390 Poster Board I-412 Purpose: To determine whether fluconazole prophylaxis was effective in decreasing the need for parenteral empiric antifungal therapy in patients with acute myeloid leukemia (AML) and persistent febrile neutropenia or suspected fungal infection at our center. Background: Prophylaxis with fluconazole in patients with severe chemotherapy-related neutropenia has been found to be beneficial in decreasing the need for parenteral antifungal therapy, and preventing superficial and invasive fungal infections and fungal infection-related mortality (Bow et al., C

APA, Harvard, Vancouver, ISO, and other styles

44

Webster, Jack, Nicole Kuderer, and Gary H. Lyman. "Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study." Cancer Control 3, no. 6 (1996): 1–4. http://dx.doi.org/10.1177/107327489600300605.

Full text

Abstract:

Background Adjuvant chemotherapy for breast cancer is frequently accompanied by neutropenia requiring dose reduction or treatment delay that can potentially compromise therapeutic effectiveness. Recombinant granulocyte-colony stimulating factor (G-CSF) reduces the duration and severity of neutropenia. Methods Nineteen patients with newly diagnosed breast cancer receiving adjuvant systemic chemotherapy met criteria for dose reduction or treatment delay due to neutropenia. All were treated with G-CSF. The mean duration of G-CSF therapy was five days. Results An increase in mean absolute neutroph

APA, Harvard, Vancouver, ISO, and other styles

45

O'Dea, Anne, Meshaal Khan, Haley Isabela Haines, et al. "Fixed dose, dose-dense capecitabine in metastatic breast cancer." Journal of Clinical Oncology 37, no. 15_suppl (2019): e12593-e12593. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e12593.

Full text

Abstract:

e12593 Background: Capecitabine (C) is the only oral chemotherapy agent for metastatic breast cancer (MBC), and compared to IV agents, can be continued indefinitely if toxicities can be managed. The optimal dose and schedule of C are not known. FDA approved dose of 2500 mg/m2 daily is associated with median PFS (progression free survival) of 4-5 months and dose reduction and discontinuation rates from toxicity of 35% and 16% respectively. According to Norton-Simon mathematical model of tumor growth in which dosing schedules are determined based on efficacy, a 7 day on and 7 days off (7-7) sche

APA, Harvard, Vancouver, ISO, and other styles

46

Iwasa, S., Y. Yamada, T. E. Nakajima, et al. "Predictive factors of outcome and clinical management of adjuvant S-1 chemotherapy for gastric cancer." Journal of Clinical Oncology 27, no. 15_suppl (2009): e15676-e15676. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15676.

Full text

Abstract:

e15676 Background: Adjuvant S-1 chemotherapy has become a standard treatment for stage II and III gastric cancer, following the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC). This study was designed to identify factors that can be used for predicting the outcome and clinical management of adjuvant S-1 chemotherapy in patients with stage II and III gastric cancer. Methods: We retrospectively examined 97 consecutive patients with stage II or III gastric cancer who received S-1 chemotherapy after gastrectomy to investigate factors associated with outcome and clinical management

APA, Harvard, Vancouver, ISO, and other styles

47

Buhlinger, Kaitlyn M., and Ian B. Hollis. "Effects of Dicloxacillin on Warfarin Dose in Patients With a Left Ventricular Assist Device." Journal of Pharmacy Practice 32, no. 6 (2018): 687–92. http://dx.doi.org/10.1177/0897190018772978.

Full text

Abstract:

Patients with a durable, continuous flow left ventricular assist device (CF-LVAD) require anticoagulation with warfarin to prevent thromboembolic events. Driveline infections (DLIs) are a common CF-LVAD complication. A common pathogen implicated in DLI is oxacillin-sensitive Staphylococcus aureus (OSSA), which is effectively treated by oral dicloxacillin. Previous published experiences have observed a significant drug interaction between dicloxacillin and warfarin resulting in decreased international normalized ratio (INR) and increased warfarin dosing requirements. We sought to analyze the ef

APA, Harvard, Vancouver, ISO, and other styles

48

Gibson, Anna M., and Claire Sutherby. "QIM19-129: Utilization of Electronic Medical Record to Improve Outcomes in the Treatment of Febrile Neutropenia." Journal of the National Comprehensive Cancer Network 17, no. 3.5 (2019): QIM19–129. http://dx.doi.org/10.6004/jnccn.2018.7138.

Full text

Abstract:

Introduction: Chemotherapy-induced febrile neutropenia is a medical emergency. Delays in time to appropriate broad spectrum antibiotic therapy significantly increase morbidity and mortality. The purpose of this project is to improve outcomes in febrile neutropenia patients within our institutions by hard wiring compliance to NCCN Guidelines and IDSA guidelines via our electronic medical record (EMR). Methods: During initial chemo teaching, patients were instructed to present for emergency care immediately on noticing a fever. Patients were given a pocket card stating that the patient had recen

APA, Harvard, Vancouver, ISO, and other styles

49

Xu, Hairong, Chun Chao, Lanfang Xu, et al. "Pattern of dose delay and dose reduction among cancer patients treated with chemotherapy." Journal of Clinical Oncology 33, no. 15_suppl (2015): e20705-e20705. http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e20705.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Byun, John, Salma Jabbour, Vimal D. Patel, and Rahul Parikh. "Outcomes after empiric radiation therapy for leukemic infiltrates of the lung: A single institution experience." Journal of Clinical Oncology 36, no. 34_suppl (2018): 225. http://dx.doi.org/10.1200/jco.2018.36.34_suppl.225.

Full text

Abstract:

225 Background: Acute leukemias (AL) may present with variable clinical findings, from incidental discovery to respiratory distress or obtundation. However, patients may progress rapidly, requiring emergent treatments including leukophoresis, chemotherapy or radiation. There is little to no data supporting the use of radiation therapy in the setting of presumed lung infiltration. We present the first known case series on the treatment of presumed leukemic lung infiltration with empiric radiation therapy (eRT). Methods: Eleven patients with AL from 2008 – 2018 were identified who were treated w

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!